In this issue:
ASCT safe and efficacious in elderly patients
Real-world utilisation of ASCT in Australia and New Zealand
Deleterious impact of comorbidities on survival in MM
Disparities in treatment patterns and outcomes in older adults with NDMM
Electronic FRAIL score may predict treatment outcomes in older adults
The association of mobilising regimen on immune reconstitution and survival
Benefit of triplet XVd seen in BOSTON maintained across age and frailty status subgroups
iStopMM: a population-based screening study for MGUS and trial of follow-up strategies
Elotuzumab for the treatment of extramedullary myeloma
TAK1: a therapeutic target for tumour progression and bone destruction
Please login below to download this issue (PDF)